
UBE4B-driven suppression of megakaryocyte maturation by HBV: A novel mechanism linking viral infection to thrombocytopenia via p53-ERK1/2 crosstalk
Brief intro:
- Author: Huinan Jiang, Yanwei Li, Xiaoguang Dou, Chao Han, Yaoxin Fan
- Journal: Cellular Signalling
- Doi: https://www.doi.org/10.1016/j.cellsig.2025.112089
- Publication Date: 2025/8/29
Abstract
Background and aim: Hepatitis B virus (HBV) infection can lead to thrombocytopenia through its effects on hematopoiesis, although the underlying mechanisms have not been fully elucidated. Platelet production involves multiple stages, including the differentiation of mature megakaryocytes, which plays a pivotal role. In this study, we assessed the variances in megakaryocyte differentiation and maturation after HBV infection and investigated the molecular mechanism involved. Methods: Different doses of HBV virus solution extracted from HepAD38 cells were co-cultured with hematopoietic stem cells that had been isolated from fresh, full-term healthy maternal cord blood through magnetic bead sorting. Label-free quantitative proteomics was employed to analyze the differential proteins during the mature megakaryocyte stages pre- and post-HBV infection, with a focus on elucidating their respective molecular mechanisms. Results: A comparative analysis revealed that HBV impeded the differentiation of fully developed megakaryocytes. Its suppressive effect was more pronounced in the later stages of differentiation, consequently leading to impaired platelet production. Proteomic analysis revealed noteworthy disparities in UBE4B protein levels in mature megakaryocytes after HBV infection. Upon transfection with lentivirus and subsequent knockdown of UBE4B in mature megakaryocytes, a noticeable alleviation of HBV's inhibitory impact was observed, accompanied by regulation of p53 and ERK1/2 expression and phosphorylation. Conclusion: HBV upregulates UBE4B expression, which inhibits p53 expression and phosphorylation while enhancing ERK1/2 expression and phosphorylation. This cascade suppresses mature megakaryocyte differentiation, resulting in impaired platelet production.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
